---
title: "U.S. stock market quick update: MEI Pharma up 66.89%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249172932.md"
description: "MEI Pharma rose 66.89%; Sarepta Therapeutics fell 18.40%, with a trading volume of USD 170 million; CRISPR Therapeutics rose 17.61%, with a trading volume of USD 101 million; Gilead Sciences rose 1.36%, with a trading volume of USD 88.45 million; AbbVie rose 0.02%, with a market capitalization of USD 338.1 billion"
datetime: "2025-07-18T13:37:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249172932.md)
  - [en](https://longbridge.com/en/news/249172932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249172932.md)
generator: "portal-rs"
---

# U.S. stock market quick update: MEI Pharma up 66.89%

**U.S. Stock Market Midday Update**

MEI Pharma rose 66.89%, with active trading. Based on recent important news:

1.  On July 18, MEI Pharma announced a $100 million private placement to initiate a Litecoin treasury strategy, with the stock price rising 78.4%.

2.  On July 18, Litecoin founder Charlie Lee joined the board, driving the stock price up 108.67%.

3.  On July 18, GSR became a digital asset and treasury management advisor, enhancing market confidence.

**Stocks with High Trading Volume in the Industry**

Sarepta Therapeutics fell 18.40%, with increased trading volume. Based on recent important news:

1.  On July 18, a patient in a gene therapy study at Sarepta died from acute liver failure, leading the FDA to investigate two similar incidents, causing the stock price to drop 16.7%.

2.  On July 17, the FDA required a black box warning to be added to the Elevidys gene therapy, which Sarepta agreed to, resulting in a 33% after-hours stock price increase.

3.  On July 17, Sarepta announced a 36% workforce reduction in response to the patient death incident, leading to a 58% stock price increase.

CRISPR Therapeutics rose 17.61%, with increased trading volume. Based on recent important news:

1.  On July 17, CRISPR Therapeutics board member George Simeon increased his holdings in the company's common stock, driving the stock price up.

2.  On July 17, analysts predicted that the gene editing drug market would grow at an average annual rate of 13%, benefiting the company's long-term development.

3.  On July 15, despite bearish investors, the market remained optimistic about the company's prospects.

Gilead Sciences rose 1.36%, with increased trading volume. Based on recent important news:

1.  On July 15, the New York Attorney General announced a settlement agreement with 48 state attorneys general, with Gilead paying $202 million, leading to a 1.36% stock price increase.

2.  On July 15, Gilead announced a partnership with the Global Fund to supply lenacapavir at cost, boosting market confidence.

3.  On July 16, Gilead executives sold shares, attracting market attention and causing stock price fluctuations.

**Stocks with High Market Capitalization in the Industry**

AbbVie rose 0.02%, with increased trading volume. Based on recent important news:

1.  On July 17, there was an order imbalance on the New York Stock Exchange, with 566,742 shares on the buy side for AbbVie, driving the stock price up.

2.  On July 16, analysts gave AbbVie an "Outperform" rating with a target price of $214.13, enhancing market confidence.

3.  On July 15, AbbVie increased its advertising spending on bipolar disorder and MDD drugs to $37.4 million, raising market attention

### Related Stocks

- [MEIP.US](https://longbridge.com/en/quote/MEIP.US.md)
- [LITS.US](https://longbridge.com/en/quote/LITS.US.md)

## Related News & Research

- [Aldebaran takes significant minority stake in packaging maker Verpack in LBO round](https://longbridge.com/en/news/300855995.md)
- [Castel launches Kelvin humanoid robot in industrial trial](https://longbridge.com/en/news/300851991.md)
- [LG Energy Solution to supply 46,100 round cells to Mercedes](https://longbridge.com/en/news/300855938.md)
- [Average analyst price target for MLP Group raised by 21.98% to PLN125.12](https://longbridge.com/en/news/300856626.md)
- [RBC Capital Sticks to Its Hold Rating for Vulcan Steel Ltd. (VSL)](https://longbridge.com/en/news/300856095.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**